Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in bDMARD-naive radiographic axial spondyloarthritis (COAST-V)
NCT02696785Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2016
- Primary completion
- Dec 2017
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in ankylosing spondylitis (AS) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Assessment of Spondyloarthritis International Society 40 Response at 16 weeks. Started May 2016; status: completed.
02
Drugs
ixekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02696785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696785.